Why Liminatus Pharma, Inc.’s (LIMN) Stock Is Up 15.61%
As of Friday, February 06, Liminatus Pharma, Inc.’s LIMN share price has surged by 15.61%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
Commentary & Analysis
Why Liminatus Pharma, Inc.’s (LIMN) Stock Is Up 12.15%
As of Friday, February 06, Liminatus Pharma, Inc.’s LIMN share price has surged by 12.15%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Liminatus Pharma, Inc.’s (LIMN) Stock Is Down 6.24%
As of Monday, September 15, Liminatus Pharma, Inc.’s LIMN share price has dipped by 6.24%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Liminatus Pharma, Inc.’s (LIMN) Stock Is Down 8.37%
As of Thursday, September 11, Liminatus Pharma, Inc.’s LIMN share price has dipped by 8.37%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Liminatus Pharma, Inc.’s (LIMN) Stock Is Down 11.84%
As of Wednesday, September 10, Liminatus Pharma, Inc.’s LIMN share price has dipped by 11.84%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | LIMN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $5.2 | $288.9 | 3% |
|
| Shares Out (Mil) | 1.0 | 54.0 | 4% |
|
| Institutional Ownership | 10.7% | 93.1% | 7% |
|
| Float (Mil) | 0.9 | 41.4 | 2% |
|
| Beta | 0.74 | 0.94 | 44% |
|
| Avg Daily Volume (000s) | 62 | 480 | 31% |
|
| Price Change (52-week) |
(97.4%) | 59.9% | 2% |
|
| Growth | LIMN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | LIMN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($13) | ($43) | 27% |
|
| EPS (TTM) | ($18.061) | ($1.500) | 3% |
|
| Operating Cash Flow (TTM) (Mil) | ($4) | ($31) | 26% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $5 | $190 | 6% |
|
| Valuation | LIMN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 14.22 | 2.84 | 93% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | LIMN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (471.5%) | (47.7%) | 0% |
|
| ROE | 294.4% | (55.0%) | 99% |
|
| Liabilities to Assets | 91.2% | 29.6% | 88% |
|
| F-Score | 2 | 3 | 7% |
|
Liminatus Pharma, Inc. did not pass any screens on 9/2/2026.
